class.freeze

From the 2026 budget audit

Which drug policies actually reduce harm — and does this programme know?

2 billion forints for a drug-policy programme on one of the most empirically contested questions in public health — without a systematic evidence review of what works.

About 500 Ft per taxpayer per year — 2 billion Ft — for drug-prevention programmes whose effectiveness against actual drug use and harm has not been independently assessed.

2 bn HUF allocation 444 HUF / taxpayer / year

What you see — and what you don't

The seen: a national drug programme with funding, offices and activities. The unseen: the harm-reduction approaches and evidence-based interventions that are not funded because the programme allocates centrally rather than by demonstrated impact on drug use and associated crime.

Objection

"A drug-free Hungary is an obvious goal — we need a strong national programme to get there."

Answer

The goal of reducing drug harm is shared; which programme activities achieve it is the empirical question. International evidence on drug policy is mixed — abstinence-only and harm-reduction models show sharply different results across different populations and drugs. Holding the budget flat is not a rejection of the goal; it is a refusal to expand spending before an evidence review identifies the components that demonstrably reduce harm.

Share if you think drug-policy spending should be evaluated against what actually works.

The analyst's verdict

Drug-Free Hungary Programme

Rationale

A drug-policy programme. The programme-mix knowledge problem applies acutely here: which drug-policy interventions reduce harm is one of the most empirically contested questions in public policy, and a central programme budget cannot resolve it by allocation. The line is not a clear retained protective function and not a concentrated rent; a Nominal Freeze holds it flat, eroding roughly 440 millió Ft of real value over a decade, pending an evidence review of which components demonstrably work.

Transition mechanism

Hold the nominal allocation flat pending an evidence review of which drug-policy components demonstrably reduce harm.

Affected groups

Drug-policy programme staff and organisations; individuals affected by drug dependency who are served by prevention and treatment programmes; no immediate displacement.

Free Society Institute

Support independent analysis

Our research is free, open, and unsponsored. If you find it valuable, help us keep it that way.